Invest in SpectraCure

Global market with high growth

The global prostate cancer market is growing and is estimated to be worth USD 100 billion by 2026. More and more men are affected due to increased life expectancy.

A real clinical need

There is currently no established effective treatment for patients with recurrent prostate cancer. This is our first priority indication.

A new treatment option  

Our treatment system has potential to replace surgery and/or hormone therapy, to provide fewer side effects and a give the patient better quality of life.

Health economic viability

Our treatment method is designed to be less resource-consuming by providing a one-off treatment, unlikecontinuous hormone therapy, and by avoiding extensive risky surgery.

Attractive business model with continuous revenue streams

The system is placed at the customer’s site for a low cost, providing a reduced barrier to entry. Recurring revenue is generated through the sale of sterile disposable equipment, with customers paying per treatment.

Potential to develop treatment for more cancer diagnoses

The treatment system has potential to be suitable for several types of internal solid tumors, not just our initial indication, recurrent prostate cancer.

This website uses cookies

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.